Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Immunovant (IMVT) Stock Price & Analysis
704 Followers
IMVT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.16 - $45.58
Previous Close$30.7
Volume729.33K
Average Volume (3M)1.10M
Market Cap
$4.46B
Enterprise Value$4.19B
Total Cash (Recent Filing)$269.93M
Total Debt (Recent Filing)$614.00K
Price to Earnings (P/E)-16.8
Beta0.89
Next Earnings
Jul 01, 2024EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding145,292,970
10 Day Avg. Volume747,614
30 Day Avg. Volume1,101,669
Standard Deviation0.24
R-Squared0.03
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)18.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-19.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-15.84
Forecast
1Y Price Target
$51.60Price Target Upside68.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Immunovant News
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageIMVT is well ahead of its competitor BHVN, with significant time and logistical advantages in running Phase 1 MAD studies in patients.
Market OpportunityManagement sees a significant opportunity for IMVT-1402 in treating Grave's disease patients, with a strong potential market in those requiring surgery.
Product LaunchThe company's management believes Vyvgart's CIDP launch will be successful due to its favorable safety profile and subcutaneous administration, which are expected to encourage patient switch.
Bears Say
Clinical Trial ConcernsManagement highlighted concerns over potential risks associated with >85% IgG reduction, such as infection risk and stopping rules for trials.
Competitive RisksA pipeline competitor is expected to report potentially competitive data, which could pose a risk to Immunovant's market position.
Financial StabilityImmunovant has a significant annual cash burn rate, which may impact its financial stability in the absence of additional funding or revenues.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $18.16 and its highest was $45.58 in the past 12 months.
What is Immunovant’s market cap?
Currently, no data Available
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Jul 01, 2024 which is in 44 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Feb 12, 2024. The company reported -$0.289 earnings per share for the quarter, beating the consensus estimate of -$0.432 by $0.143.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -$0.43.
How many shares outstanding does Immunovant have?
Immunovant has 145,292,970 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.289 in its last earnings report, beating expectations of -$0.432. Following the earnings report the stock price went up 3.352%.
Which hedge fund is a major shareholder of Immunovant?
Among the largest hedge funds holding Immunovant’s share is Perceptive Advisors LLC. It holds Immunovant’s shares valued at 96M.
---
Immunovant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.60 (68.08% Upside)
$51.60 (68.08% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.35%
12-Months-Change
Fundamentals
Return on Equity
-44.51%
Trailing 12-Months
Asset Growth
55.94%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
---
IMVT Stock 12 Month Forecast
Average Price Target
$51.60
▲(68.08% Upside)
Technical Analysis
RAPT Therapeutics
―
Kala Pharmaceuticals
―
Adverum Biotechnologies
―
Arvinas Holding Company
―
Best Analysts Covering IMVT
1 Year
1 Year Success Rate
11/20 ratings generated profit
1 Year Average Return
+67.27%
reiterated a buy rating 3 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +67.27% per trade.
---